Validating a case definition for chronic kidney disease using administrative data.

BACKGROUND Administrative data are commonly used for surveillance of chronic medical conditions. The purpose of this study was to determine the validity of an algorithm derived from administrative data for identifying chronic kidney disease (CKD) compared to the reference standard of estimated glomerular filtration rate (eGFR). METHODS We identified adults from the province of Alberta with at least two outpatient serum creatinine measurements within a 1-year time period. Validity indices were estimated for CKD using up to 3 years of administrative data (physician billing claims and hospital discharge abstracts) for various case-definition combinations. For each algorithm, the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were calculated against two reference standard definitions of CKD (two eGFR measurements <60 mL/min/1.73m(2) or mean eGFR < 30 mL/min/1.73m(2)). RESULTS A total of 321 293 eligible subjects were identified. Irrespective of the algorithm, sensitivities for defining CKD (eGFR < 60 mL/min/1.73m(2)) using administrative codes were low. A case-definition algorithm employing two physician claims or one hospitalization within a 2-year period had sensitivity of 19.4%, specificity of 97.2%, PPV of 60.1% and NPV of 84.8% for detecting CKD. Estimates of sensitivity were higher when <30 mL/min/1.73m(2) was used as the reference standard, although PPVs were lower and consistently less than 50%. CONCLUSION These results, using eGFR as a reference standard, suggest that administrative data have insufficient sensitivity and PPV for CKD surveillance, although they may be useful when highly specific algorithms are required for research purposes.

[1]  Amit X Garg,et al.  Validity of administrative database coding for kidney disease: a systematic review. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[2]  D. Levy,et al.  Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. , 1999, Kidney international.

[3]  T. Greene,et al.  Blood Pressure Control, Proteinuria, and the Progression of Renal Disease , 1995, Annals of Internal Medicine.

[4]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[5]  Ethan M Balk,et al.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  Gary L Myers,et al.  Validation of CKD and related conditions in existing data sets: A systematic review. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[7]  G. Beck,et al.  The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease , 1994 .

[8]  P. Roderick,et al.  A population-based study of the incidence and outcomes of diagnosed chronic kidney disease. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[9]  J. Avorn,et al.  Identification of individuals with CKD from Medicare claims data: a validation study. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[10]  A. Murray,et al.  Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. , 2005, Journal of the American Society of Nephrology : JASN.

[11]  Karen Tu,et al.  Accuracy of administrative databases in identifying patients with hypertension , 2007, Open medicine : a peer-reviewed, independent, open-access journal.

[12]  Tom Greene,et al.  Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. , 2002, JAMA.

[13]  A. Bello,et al.  Chronic kidney disease: the global challenge , 2005, The Lancet.

[14]  Hude Quan,et al.  Validation of a Case Definition to Define Hypertension Using Administrative Data , 2009, Hypertension.

[15]  Katrin Uhlig,et al.  Low rates of testing and diagnostic codes usage in a commercial clinical laboratory: evidence for lack of physician awareness of chronic kidney disease. , 2005, Journal of the American Society of Nephrology : JASN.

[16]  B. Manns,et al.  The Southern Alberta Renal Program database: a prototype for patient management and research initiatives. , 2001, Clinical and investigative medicine. Medecine clinique et experimentale.

[17]  J. Yudkin,et al.  Proteinuria and progressive renal disease: birth weight and microalbuminuria. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[18]  R. Poveda,et al.  Goodpasture syndrome during the course of a Schönlein-Henoch purpura. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[19]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[20]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[21]  H. Clark,et al.  Serum creatinine is an inadequate screening test for renal failure in elderly patients. , 2003, Archives of internal medicine.

[22]  P Menè,et al.  Calcium channel blockers: what they can and what they can't do. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[23]  Janet E Hux,et al.  Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. , 2002, Diabetes care.

[24]  S. Klahr The modification of diet in renal disease study. , 1989, The New England journal of medicine.

[25]  Jennifer MacRae,et al.  Overview of the Alberta Kidney Disease Network , 2009, BMC nephrology.

[26]  F. Sacks,et al.  Pravastatin for Secondary Prevention of Cardiovascular Events in Persons with Mild Chronic Renal Insufficiency , 2003, Annals of Internal Medicine.

[27]  T. Hostetter,et al.  Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. , 2004, Journal of the American Society of Nephrology : JASN.

[28]  G. Robbins,et al.  The development of the National Diabetes Surveillance System (NDSS) in Canada. , 2001, Chronic diseases in Canada.

[29]  Raymond Vanholder,et al.  The burden of kidney disease: improving global outcomes. , 2004, Kidney international.

[30]  O. Djurdjev,et al.  Screening for renal disease using serum creatinine: who are we missing? , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[31]  S. Yusuf,et al.  Renal Insufficiency as a Predictor of Cardiovascular Outcomes and the Impact of Ramipril: The HOPE Randomized Trial , 2001, Annals of Internal Medicine.

[32]  D. Rothenbacher,et al.  Prevalence of chronic kidney disease in population-based studies: Systematic review , 2008, BMC public health.

[33]  R. Foley,et al.  CKD surveillance using administrative data: impact on the health care system. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[34]  R. Atkins,et al.  Chronic kidney disease in the general population. , 2005, Advances in chronic kidney disease.

[35]  D. Bates,et al.  Diabetes, hemoglobin A(1c), cholesterol, and the risk of moderate chronic renal insufficiency in an ambulatory population. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.